Koschmieder, Steffen

PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis.

Huang, G., Zhang, P., Hirai, H., Elf, S., Yan, X., Chen, Z., Koschmieder, S., Okuno, Y., Dayaram, T., Growney, J. D., et al. (2008) · Nature Genetics

Genomics and Chromatin DynamicsAcute Myeloid Leukemia Research

Cited by 259

The C/EBPδ tumor suppressor is silenced by hypermethylation in acute myeloid leukemia

Agrawal, S., Hofmann, W.-K., Tidow, N., Ehrich, M., Boom, D. V. D., Koschmieder, S., Berdel, W. E., Serve, H., & Müller-Tidow, C. (2007) · Blood

Acute Myeloid Leukemia ResearchEpigenetics and DNA Methylation

Cited by 119

A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia

Steidl, U., Steidl, C., Ebralidze, A., Chapuy, B., Han, H.-J., Will, B., Rosenbauer, F., Becker, A., Wagner, K., Koschmieder, S., et al. (2007) · Journal of Clinical Investigation

Acute Myeloid Leukemia ResearchGenomics and Chromatin Dynamics

Cited by 114

JAK2-V617F and interferon-α induce megakaryocyte-biased stem cells characterized by decreased long-term functionality

Rao, T. N., Hansen, N., Stetka, J., Luque Paz, D., Kalmer, M., Hilfiker, J., Endele, M., Ahmed, N., Kubovcakova, L., Rybarikova, M., et al. (2021) · Blood

Myeloproliferative Neoplasms: Diagnosis and TreatmentHematopoietic Stem Cell Transplantation

Cited by 72

Role of Transcription Factors C/EBPa and PU.1 in Normal Hematopoiesis and Leukemia

Koschmieder, S., Rosenbauer, F., Steidl, U., Owens, B. M., & Tenen, D. G. (2005) · International Journal of Hematology

Acute Myeloid Leukemia ResearchGenomics and Chromatin Dynamics

Cited by 72

Bone marrow laminins influence hematopoietic stem and progenitor cell cycling and homing to the bone marrow

Susek, K. H., Korpos, E., Huppert, J., Wu, C., Savelyeva, I., Rosenbauer, F., Müller-Tidow, C., Koschmieder, S., & Sorokin, L. (2018) · Matrix Biology

Hematopoietic Stem Cell TransplantationCell Adhesion Molecules Research

Cited by 58

BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis

Verstovsek, S., Al-Ali, H. K., Mascarenhas, J., Perkins, A., Vannucchi, A. M., Mohan, S. R., Scott, B. L., Woszczyk, D., Koschmieder, S., García-Delgado, R., et al. (2022) · Future Oncology

Myeloproliferative Neoplasms: Diagnosis and TreatmentAcute Myeloid Leukemia Research

Cited by 41